Blog

Closing adds $5 million in marketable securities, strengthens financial position, and complements MIRA’s advancing programs including Ketamir-2 and MIRA-55

MIAMI, FLORIDA / ACCESS Newswire / September 30, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that it has completed its acquisition of SKNY Pharmaceuticals, Inc. (“SKNY”).

As part of the transaction, SKNY fulfilled all closing obligations, contributing $5 million in marketable securities to MIRA, further strengthening the Company’s balance sheet.

“The successful closing of the SKNY acquisition marks a pivotal milestone for MIRA, both financially and strategically,” said Erez Aminov, CEO of MIRA. “We are expanding our pipeline into obesity and nicotine addiction with SKNY-1, while continuing to advance Ketamir-2 through clinical development and progressing MIRA-55 as a novel approach to inflammatory and nociceptive pain. Together, these programs position MIRA to address major unmet needs across some of the largest healthcare markets.”

SKNY-1: A Next-Generation Oral Therapy Candidate for Obesity and Smoking Cessation

SKNY-1 is a differentiated oral drug candidate designed to modulate CB1, CB2, and MAO-B pathways to address energy storage, lipid metabolism, appetite, cravings, and reward – without the psychiatric side effects that limited earlier CB1-targeting drugs.

Key preclinical findings include:

• Up to 30% reduction in body weight without muscle loss in validated animal models.

• Marked modification of metabolic parameters.

• Reversal of nicotine craving and high-calorie food cravings, supporting dual therapeutic potential.

• Favorable CNS safety profile compared with prior CB1-targeting agents.

Dr. Itzchak Angel, Chief Scientific Advisor at MIRA, commented:

“SKNY-1’s unique biased CB1 signaling and favorable CB2/MAO-B activity translate into robust and broad-spectrum efficacy across metabolic syndrome, obesity, and addiction models while addressing the safety limitations of earlier agents. We believe it has the potential to be best-in-class.”

Ketamir-2: Clinical-Stage Development in Neuropathic Pain

On September 22, 2025, MIRA announced favorable topline results from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial of Ketamir-2, its proprietary next-generation ketamine analog. The study demonstrated Ketamir-2 was safe and well tolerated across all dose levels, with predictable absorption, once-daily dosing potential, and no CNS side effects typically associated with ketamine.

Preclinical studies further support Ketamir-2’s potential in neuropathic pain, depression, and PTSD, reinforcing its profile as a differentiated non-scheduled therapeutic.

MIRA-55: A Novel Approach to Inflammatory Pain

MIRA-55, the Company’s oral pharmaceutical cannabis-derived candidate, has shown preclinical results in inflammatory and nociceptive pain comparable to morphine. Unlike opioids, MIRA-55 is designed to provide pain relief without addictive risk, positioning it as a promising next-generation analgesic.

Market Opportunity

Obesity, metabolic disorders, nicotine addiction, neuropathic pain, nociceptive and inflammatory pain, depression, and post-traumatic stress disorder (PTSD) represent some of the largest and fastest-growing healthcare markets, each with high prevalence and substantial unmet medical need.

MIRA is directly addressing these areas through its pipeline:

• SKNY-1 for obesity and nicotine addiction.

• Ketamir-2 for neuropathic pain with potential in depression and PTSD.

• MIRA-55 for inflammatory and nociceptive pain.

• Additional preclinical programs targeting cognitive impairment and related neuropsychiatric disorders.

Together, these programs underscore MIRA’s strategy of advancing differentiated, non-opioid, and non-addictive therapeutic options aimed at improving patient outcomes in high-value markets.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.

For more information, please visit www.mirapharmaceuticals.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact:
Helga Moya
info@mirapharma.com
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire

TAMPA, FL / ACCESS Newswire / September 30, 2025 / Wellgistics Health, Inc. (“Wellgistics Health” or the “Company”) (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced a strategic collaboration with TheracosBio, the manufacturer of Brenzavvy® (bexagliflozin), to make diabetes medications more affordable and accessible across the U.S. healthcare system.

The joint effort leverages Wellgistics Health’s “maker-to-taker” platform – a direct pipeline that connects manufacturers to pharmacies and patients while bypassing costly intermediaries. With over 6,500 independent and chain pharmacies in its national network, Wellgistics Health will expand access to Brenzavvy through both traditional retail and direct-to-patient delivery models.

Key Benefits of the Collaboration

• Expanded Access – Brenzavvy will be made available through the Wellgistics Health network of 6,500+ independent pharmacies, as well as participating chain pharmacies, reaching patients nationwide.

• Affordability – By eliminating middlemen, this initiative is expected to lower costs to levels often below typical insurance copayments, easing patient cost burdens and increasing adherence.

• Pharmacist Empowerment – Participating pharmacies will provide patient counseling, adherence support, and care coordination.

• AI & Technology Integration – The Wellgistics Tech & Hub platform, powered by AI-driven modules, will streamline eligibility checks, claims adjudication, adherence tracking, and reporting.

Addressing an Urgent Need

Type 2 diabetes affects over 37 million Americans and costs the U.S. an estimated $327 billion annually. Yet only one in eight eligible adults receives an SGLT-2 inhibitor, largely due to out-of-pocket costs that can exceed $500 per month.

Brenzavvy, a once-daily oral treatment, offers a cost-effective option within the SGLT-2 inhibitor class, designed to improve glycemic control in adults when used in conjunction with diet and exercise.

Executive Commentary

“Millions of Americans with type 2 diabetes still face affordability and access barriers at the pharmacy counter,” said Brian Connelly, CEO of TheracosBio. “Through Wellgistics Health’s streamlined approach, we are expanding access to Brenzavvy, helping patients afford their medications while empowering pharmacists to deliver meaningful care.”

“Direct-to-patient affordability and access programs are a cornerstone of Wellgistics Health’s mission,” said Brian Norton, CEO of Wellgistics Health. “We are pioneering innovative models designed to not only expand patient access but also bring new levels of transparency and affordability to the healthcare system. By leveraging our technology-enabled platform and our national network of independent and chain pharmacies, we are striving to ensure powerful therapies like Brenzavvy are delivered efficiently, responsibly, and at a cost that patients can sustain.”

Everyone Wins

• Patients pay less and gain greater access to a vital class of diabetes medications.

• Pharmacies receive fair compensation and tools to enhance patient care.

• Employers and Health Plans see expedited and transparent savings without waiting for rebate reconciliations.

• Manufacturers gain a direct, efficient channel to reach patients and expand therapy adoption.

Execution Roadmap

Brenzavvy will be integrated into the Wellgistics Tech & Hub and Distribution platform beginning in Q4 2025, enabling immediate patient onboarding through affiliated pharmacies and direct-to-patient channels.

Q4 2025 rollout positions WGRX for near-term revenue impact.

This collaboration underscores Wellgistics Health’s aim to be a disruptive force in pharmaceutical distribution, redefining how therapies move from manufacturer to patient with transparency, affordability, and scale.

About TheracosBio

TheracosBio is a biopharmaceutical company dedicated to developing and commercializing therapies that address unmet needs in chronic disease management. Its lead product, Brenzavvy, was developed to provide an effective, affordable SGLT-2 inhibitor option for adults with type 2 diabetes.

For full prescribing information, visit www.theracosbio.com.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health’s filings with the SEC, available at www.sec.gov.

Media & Investor Contact

Media:
media@wellgisticshealth.com

Investor Relations:
IR@wellgisticshealth.com

Investor Relations Contact

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com

SOURCE: Wellgistics Health, Inc.

View the original press release on ACCESS Newswire

Company recognized for innovation, leadership and workplace culture

SAN FRANCISCO, CA / ACCESS Newswire / September 30, 2025 / Sama, delivering data certainty for enterprise AI through tech-enabled annotation, validation and evaluation services, today announced multiple international honors, awarding Sama for its workplace culture, company growth, technology innovation and business leadership.

At the 2025 Africa Digital Economy Awards, Sama was named Most Innovative BPO Provider of the Year, recognized for its proprietary platform and human-in-the-loop (HITL) approach that powers complex AI model training in autonomous vehicles, agriculture, retail and healthcare. The platform combines ML-assisted tools with expert annotators to deliver industry-leading accuracy and efficiency from the first data set.

Sama Vice President of Global Service Delivery, Annepeace Alwala, was also recognized at the Digital Economy Awards, winning Digital Woman of the Year award for her leadership in scaling Sama’s impact in East Africa and advancing opportunities for women in technology. Alwala oversees a workforce of more than 3,000 employees across Kenya and Uganda and has helped drive milestones including achieving B Corp certification and forging national partnerships to expand youth employment in the digital economy.

In addition, Sama received the Impact Sourcing Honor from Elevate Group, which recognizes companies that create economic opportunities for people with the greatest barriers to work. The award highlights Sama’s proven impact sourcing model, through which the company has helped nearly 70,000 people lift themselves out of poverty via formal digital-economy employment.

Sama was also named to the 2025 Global Inspiring Workplaces list, following earlier recognition among the top three Inspiring Workplaces in the Middle East and Africa. This global accolade highlights Sama’s investments in wellbeing, inclusion and professional growth that have created measurable outcomes for employees and customers.

“Our mission is to prove that responsible AI delivers enterprise results and social impact,” said Wendy Gonzalez, CEO of Sama. “These various awards validate the systems we’ve built and our world class team. From our inception, Sama has remained committed to delivering industry-leading AI solutions alongside life-changing opportunities for individuals who previously had no access into the digital economy. We are honored to be recognized for these efforts.”

These achievements build on a year of recognition for Sama. In 2025, the company was named one of America’s Greatest Workplaces for Women and Greatest Workplaces for Inclusion & Diversity by Newsweek, and earned the Virtual Fitting Room Solution Provider of the Year award at the RetailTech Breakthrough Awards.

***

About Sama

Sama delivers data certainty for enterprise AI through tech-enabled annotation, validation and evaluation services. By combining advanced platforms with expert human judgment, Sama helps some of the world’s largest companies, including 30% of the Fortune 50, move AI models from development to production with confidence. With thousands of skilled data professionals and industry-leading quality guarantees, Sama tackles the critical challenge that over 63% of AI models fail to reach production due to poor data quality.

Founded in 2008, Sama has delivered more than 40 billion data points and created employment opportunities that have helped over 70,000 people lift themselves out of poverty. As a certified B Corporation, Sama is committed to advancing both technological innovation and social impact. Learn more at www.sama.com.

Sama media contact

sama@songuepr.com

SOURCE: Sama

View the original press release on ACCESS Newswire

Early Patient Feedback Points to Clearer Understanding of Results and Smoother Treatment Planning

GRAND RAPIDS, MICHIGAN / ACCESS Newswire / October 1, 2025 / Quintessence Psychiatry, a telepsychiatry practice led by Nona Kocher, MPH, MD, has adopted Mentavi Health‘s asynchronous Diagnostic Evaluation to offer patients a scientifically rigorous, accessible alternative to full neuropsychological testing. The Mentavi Diagnostic Evaluation is clinically validated (and now peer-reviewed and published in the The Journal of Clinical Psychiatry*) for the diagnosis of ADHD in adults.

Quintessence Psychiatry previously referred ADHD inquiries to external neuropsychology providers – a process that can involve weeks to months of waiting and hundreds of dollars in testing costs for a broad battery of tests many patients don’t need. Early experiences at Quintessence show patients can complete the self-directed evaluation at their convenience (often at home) and return to the clinic with a report reviewed by a licensed psychologist to guide treatment conversations.

“Mentavi gives my patients a focused, evidence-based ADHD evaluation at a price and speed they can actually use,” said Dr. Nona Kocher, psychiatrist and founder of Quintessence Psychiatry. “It adds rigor to my workflow and helps patients understand what the findings mean, so we can move forward with an informed plan rather than sending them into a lengthy outside testing queue.”

In the initial phase of adoption, three patients have completed the evaluation, with positive feedback on the clarity of the results and visuals. Patients typically review the Mentavi report with Dr. Kocher at a follow-up visit to discuss how ADHD symptoms may be affecting daily life and to consider therapy and/or medication options. “The report graphics make it easier for patients to grasp their results at a glance, which improves shared decision making,” Dr. Kocher added.

Beyond speed and accessibility, the Mentavi Diagnostic Evaluation integrates cleanly into Quintessence’s care model, which emphasizes applying modern, science-based methods – including, when appropriate, pharmacogenetic testing – to reduce trial and error in treatment selection.

“We are pleased that our validated diagnostic approach can serve Quintessence Psychiatry by removing barriers to timely access to care for their patients. This is what our approach was designed for,” said Keith Brophy, CEO of Mentavi Health.

“Clinicians like Dr. Kocher tell us Mentavi helps them triage ADHD inquiries efficiently and focus their time where it matters most – on individualized care,” said Mentavi Health Chief Medical Officer Barry K. Herman, M.D., MMM. “We’re pleased to support private practices with an evaluation that is clinically validated, rigorous, patient-friendly, and easy to fold into existing workflows.”

Quintessence intends to continue offering the Mentavi Diagnostic Evaluation for appropriate ADHD cases and to gather ongoing patient feedback to inform clinical workflows.

* Peer‑reviewed validation: Results of Mentavi’s diagnostic validation study were published in The Journal of Clinical Psychiatry on September 8, 2025 (J Clin Psychiatry 2025;86(3):25m15846; doi:10.4088/JCP.25m15846).

About Quintessence Psychiatry

Quintessence Psychiatry is a patient-centered telepsychiatry practice led by Nona Kocher, MD, offering comprehensive evaluations, medication management, and individualized care plans. The practice integrates modern, evidence-based methods to help patients move from assessment to actionable next steps. For more information, visit quintessencepsychiatry.com.

About Mentavi Health

Established as ADHD Online in 2018, Mentavi Health has evolved to encompass a broader range of mental health services. With the mission to make high-quality ADHD assessments accessible to all, Mentavi has grown to address not only ADHD but also the most common related mental health conditions. The nationwide Mentavi Diagnostic Evaluation and various treatment options showcase the company’s commitment to providing comprehensive, accessible, and compliant online mental health care, grounded in clinical validation and trust. For more information, visit mentavi.com.

Contact Information

Tim Cox
ZingPR for Mentavi
tim@zingpr.com

SOURCE: Mentavi Health

Related Images

View the original press release on ACCESS Newswire

HAYWARD, CALIFORNIA / ACCESS Newswire / October 1, 2025 / Biolog, Inc., a trusted leader in microbial identification and testing, today announced its new Foodborne Pathogen Testing Service, out of it’s Newark, Delaware location, expanding its portfolio to include ISO-certified molecular assays that safeguard food safety and support regulatory compliance for food producers of all sizes.

The new service delivers rapid, scientifically validated detection across various matrices for the five most common foodborne pathogens: E. coli O157 (including H7), Salmonella, Listeria monocytogenes, Campylobacter, and Cronobacter.

“We’ve heard from many of our customers in food manufacturing that they are under intense pressure to ensure safety while keeping production on track,” said Robert Wicke, CEO at Biolog. “As their trusted microbial testing expert, we are thrilled to be able to offer this new service that helps them protect their brands, avoid costly recalls, and stay ahead of evolving regulatory requirements.”

With 40+ years of microbial expertise, Biolog Lab Services delivers a best-in-class combination of speed and dependability in microbial testing services. Customers benefit from reliable results in as little as three days, backed by AOAC, AFNOR validations, and ISO 17025 certification, ensuring adherence to the strictest global standards. The service offers high sensitivity and specificity at a competitive price point, while being grounded in USDA-approved and FDA-endorsed molecular science.

Biolog’s strategic proximity to major agricultural hubs gives regional produce, beef, and poultry producers a critical edge. By offering certified results in days rather than weeks, Biolog enables these producers to stay compliant, reduce scrap costs, and make confident decisions faster.

Biolog’s expansion into foodborne pathogen testing reinforces its role as a comprehensive partner for microbial testing solutions, delivering the expertise, speed, and dependability food producers need.

To learn more about Foodborne Pathogen Testing, request a quote, or explore Biolog’s comprehensive microbial testing portfolio, please visit www.biolog.com.

About Biolog
Biolog has the tools, services, and support to provide comprehensive cellular characterization and multi-omic identification for thousands of bacteria, yeast, and fungal species. Our products enable the growth and phenotypic profiling of microbial and mammalian cells for a wide range of applications, including pre-reduced media and gloveless chambers that support culturing organisms under strictly anaerobic conditions. Learn more at biolog.com.

SOURCE: Biolog, Inc.

View the original press release on ACCESS Newswire

HESPERIA, CA / ACCESS Newswire / September 30, 2025 / 5E Advanced Materials, Inc. (“5E” or the “Company”) (Nasdaq:FEAM)(ASX:5EA), a development stage company focused on becoming a vertically integrated global leader and supplier of refined borates and advanced boron derivative materials, hosted its Fiscal Year 2025 year-end conference call yesterday.

During the call, the Company’s Chief Executive Officer, Paul Weibel, highlighted the transition from development to commercial readiness, underscoring achievements that position 5E as the future cornerstone in the global boron supply chain:

• Robust Project Economics – The recently published SK-1300 Preliminary Feasibility Study (PFS) validated Phase 1 of the Fort Cady project with a pre-tax NPV7 of US$725 million, 19.2% IRR, and a 39.5-year life of mine. The study estimates ~US$3.7 billion in pre-tax free cash flow and outlines a scalable operation supported by 5.4 million short tons of boric acid reserves.

• Commercial Traction Expands – 14 customers have now successfully qualified 5E’s high-purity boric acid across industries including specialty glass, fiberglass, agriculture, defense, and chemicals.

• Full-scale Product Testing -Following a successful logistics and furnace trial, 5E is ready to complete full-scale product testing with a Tier-1 specialty glass manufacturer. Twenty tons of high-quality boric acid are produced, and shipment is imminent. Additional large LCD glass manufacturers are already queued for similar testing, demonstrating strong near-term commercial pull.

• Financing Pathway Strengthened – The Company secured a non-binding LOI from U.S. EXIM Bank for a potential US$285 million debt facility. In parallel, 5E is ready to apply for EXIM’s Engineering Multiplier program targeting US$8.5-10 million to fund FEED engineering.

• Critical Minerals List – The United States Geological Survey (USGS) recently closed its public comment period on the draft critical minerals list. Per the Federal Register, the Company, along with eight other groups, submitted comment letters in favor of adding boron to the list.

• Roadmap to Final Investment Decision (FID) – With early FEED activities underway, 5E remains on track to reach FID by mid-2026. Upcoming catalysts include completion of full-scale customer tests, securing offtake agreements, advancing project financing, and the potential inclusion of boron on the U.S. Geological Survey’s Critical Minerals List.

Mr. Weibel emphasized the strategic importance of boron for U.S. supply chain resilience, particularly as global producers face cost pressures and restructuring. “Fiscal 2025 marked a true inflection year for 5E,” said Mr. Weibel. “We are building a U.S.-based boron supply chain at a time when demand is rising sharply, supply shortfalls are projected as early as 2026, and the market needs a new and reliable domestic producer.”

A replay of the Fiscal Year 2025 earnings call is now available at the following link HERE.

About 5E Advanced Materials, Inc.

5E Advanced Materials, Inc. (Nasdaq:FEAM)(ASX:5EA) is focused on becoming a vertically integrated global leader and supplier of refined borates and advanced boron materials, complemented by calcium-based co-products, and potentially other by-products such as lithium carbonate. The Company’s mission is to become a supplier of these critical materials to industries addressing global decarbonization, energy independence, food, national security, and the defense sector. The Company believes factors such as government regulation and incentives focused on domestic manufacturing and supply chains and capital investments across industries will drive demand for end-use applications like solar and wind energy infrastructure, neodymium-ferro-boron magnets, defense applications, lithium-ion batteries, and other critical material applications. The business is based on the Company’s large domestic boron resource, which is located in Southern California and designated as Critical Infrastructure by the Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency.

Forward Looking Statements

Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, and include, but are not limited to, statements regarding the Company’s ability to progress full-scale product testing, advance the qualification of our boric acid with customers, enter into offtake agreements, receive any proceeds under any of EXIM’s loan programs, boron’s potential to be placed on the USGS critical minerals list, achieve key milestones on the path toward a potential Final Investment Decision, and become a vertically integrated global leader in borates and advanced boron materials. Any forward-looking statements are based on 5E’s current expectations, forecasts, and assumptions and are subject to a number of risks and uncertainties that could cause actual outcomes and results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, statements regarding the Company’s ability to progress full-scale product testing, advance the qualification of our boric acid with customers, enter into long-term supply agreements, receive any proceeds under any of EXIM’s loan programs, boron’s potential to be placed on the USGS critical minerals list, achieve key milestones on the path toward a potential Final Investment Decision, and become a vertically integrated global leader in borates and advanced boron materials. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled ‘Risk Factors’ in 5E’s most recent Annual Report on Form 10-K and its other reports filed with the SEC. Forward-looking statements contained in this announcement are based on information available to 5E as of the date hereof and are made only as of the date of this release. 5E undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing 5E’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of 5E.

For further information contact:
Michael MacMillan or Paola Ashton
PRA Communications
team@pracommunications.com
Ph: +1 (604) 681-1407

SOURCE: 5E Advanced Materials, Inc.

View the original press release on ACCESS Newswire

VANCOUVER, BC / ACCESS Newswire / September 30, 2025 / CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (“CoTec” or the “Company”) is pleased to note today’s press release by HyProMag USA, LLC (“HyProMag USA”), its U.S.-based joint venture rare earth permanent magnet recycling and manufacturing company.

HyProMag USA announced it has purchased three skid-mounted Inserma Anoia S.L (“Inserma”) magnet and Printed Circuit Board (“PCB”) separation units. The Inserma and PCB units can be co-located at hyperscale data centers, shredding, recycling or HyProMag facilities. These Inserma units rapidly remove (at <2 seconds per hard disk drive ("HDD")) the voice coil motor ("VCM") containing the rare earth magnet, providing a highly concentrated feed for subsequent Hydrogen Processing of Magnet Scrap ("HPMS") by HyProMag USA at the Texas facility. The technology package will further complete the separation and removal of the PCB, which contains precious metals, for recycling and sale. The three units will be located and operated by Intelligent Lifecycle Solutions, LLC ("ILS") as it continues stockpiling of feedstock for the Fort Worth facility.

Julian Treger, Chief Executive of CoTec commented: “We are very excited to see the rapid development of the Inserma partnership. Pre-processing technologies are a key enabler and competitive advantage for HyProMag USA as it progresses with the purchase of feedstock. The purchase of these Inserma units is the start of the roll-out of pre-processing technologies to support feedstock suppliers for our magnet recycling and manufacturing facilities. The Company is continuing to progress its discussions with the rapidly expanding hyperscale data center providers and offers a closed loop and secure recycling network within the United States at the lowest cost and lowest carbon footprint. Furthermore, the batch process design of the Texas facility with separate individual feedstock waste streams supports consistent finished grades of magnets and blocks.

For further information, please refer to HyProMag USA’s press release, available at: www.hypromagusa.com

About HyProMag USA

HyProMag USA LLC is owned 50:50 by CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (“CoTec”) and HyProMag Limited. HyProMag Limited is 100 percent owned by Maginito Limited which is owned on a 79.4/20.6 percent basis by Mkango Resources Ltd. (AIM/TSXV:MKA) and CoTec.

About CoTec

CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) is redefining the future of resource extraction and recycling. Focused on rare earth magnets and strategic materials, CoTec integrates breakthrough technologies with strategic assets to unlock secure, sustainable, and low-cost supply chains for the United States and its allies.

CoTec’s mission is clear: accelerate the energy transition while strengthening U.S. economic and national security. By investing in and deploying disruptive technologies, the Company delivers capital-efficient, scalable solutions that transform marginal assets, tailings, waste streams, and recycled products into high-value critical minerals.

From its HyProMag USA magnet recycling joint venture in Texas, to iron tailings reprocessing in Québec, to next-generation copper and iron solutions backed by global majors, CoTec is building a diversified portfolio with long-term growth, rapid cash flow potential, and high barriers to entry. The result is a game-changing platform at the intersection of technology, sustainability, and strategic materials.

For more information, please visit www.cotec.ca

For further information, please contact:

Braam Jonker – (604) 992-5600

Forward-Looking Information Cautionary Statement

Statements in this press release regarding the Company and its investments which are not historical facts are “forward-looking statements” which involve risks and uncertainties, including statements relating to the Company’s interest in and the proposed expansion of HyProMag USA and management’s expectations with respect to its current and potential future investments, including HyProMag USA, and the benefits to the Company which may be implied from such statements. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements, due to known and unknown risks and uncertainties affecting the Company, including but not limited to resource and reserve risks; environmental risks and costs; labor costs and shortages; uncertain supply and price fluctuations in materials; increases in energy costs; labor disputes and work stoppages; leasing costs and the availability of equipment; heavy equipment demand and availability; contractor and subcontractor performance issues; worksite safety issues; project delays and cost overruns; extreme weather conditions; and social and transport disruptions. For further details regarding risks and uncertainties facing the Company please refer to “Risk Factors” in the Company’s filing statement dated April 6, 2022, a copy of which may be found under the Company’s SEDAR profile at www.sedar.com. The Company assumes no responsibility to update forward-looking statements in this press release except as required by law. Readers should not place undue reliance on the forward-looking statements and information contained in this news release and are encouraged to read the Company’s continuous disclosure documents which are available on SEDAR at www.sedarplus.ca.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: CoTec Holdings Corp.

View the original press release on ACCESS Newswire

• All-cash purchase price of approximately $700,000;

• Eventdex serves 60+ customers; generated ~$750K in 2024 revenue and ~$500K year-to-date 2025.

• Combination unifies Map D’s floor mapping with Eventdex’s registration and badge printing-and fast-tracks Nextech3D.ai’s blockchain ticketing roadmap.

NEW YORK CITY, NY AND TORONTO, ON / ACCESS Newswire / September 30, 2025 / Nextech3D.ai (CSE:NTAR)(OTCQX:NEXCF)(FSE:EP2) (“Nextech3D.ai” or the “Company”), an AI-first event-technology and 3D solutions provider, today announced it has signed a binding letter of intent (LOI) to acquire Eventdex, a registration and badge-printing software company serving 60+ customers with approximately $750,000 in revenue for 2024 and approximately $500,000 year-to-date 2025.

Under the LOI, the purchase price is approximately $700,000, payable entirely in cash subject to customary adjustments. A 30-day due diligence period has commenced; subject to satisfactory completion of diligence, negotiation of definitive agreements, and customary approvals, the parties expect to proceed to closing on or before October 19th, 2025.

Accelerating Blockchain Ticketing

Nextech3D.ai’s planned blockchain ticketing solution-targeted to launch following the close-will be accelerated by Eventdex’s registration and identity stack. Together, the companies intend to deliver:

• Fraud and bot resistance: tokenized tickets with provable authenticity and optional KYC/ID verification.

• Programmable rights: VIP access, time-based perks, or sponsor benefits embedded into the ticket.

• Secondary market economics: on-chain rules to enable royalties and shared economics on verified resales.

• Unified attendee journey: from floor plan & sales (Map D) → registration & check-in (Eventdex) → secure, tokenized tickets and analytics in one platform.

Strategic Rationale

• One-stop event suite: combine Map D; interactive floor plans, exhibitor management, sponsorships, mobile apps, ticketing with Eventdex; registration, on-site check-in, badge printing.

• Commerce-first dashboard: single view of ticket sales, registrations, exhibitor upgrades, sponsorships, and on-site activity.

• Cross-sell & upsell: attach ticketing, mobile apps, AR navigation, and sponsorship packages across the combined customer base.

• Operational simplicity: fewer vendors, faster show setup, shorter lines, higher NPS.

Management Commentary

Evan Gappelberg, CEO of Nextech3D.ai comments, “Event organizers want one partner who can help them sell more, operate faster, and secure the attendee experience. By adding Eventdex’s registration and on-site badge printing to Map D-and by accelerating our blockchain ticketing launch-we’re moving even faster toward a truly one-stop event operating system.”

Eventdex Co-Founders Durga and Raj comments

“The technology market is at an inflection point since the industrial revolution with upcoming technologies of AI and Blockchain. As engineers, we were always into building products. We have now finally found the match to take our products to the next level and expand the market reach with the leadership of Evan”.

About Eventdex

Eventdex provides event registration, on-site check-in, and badge printing solutions for conferences, trade shows, and corporate events. The company serves 60+ customers and reported approximately $750K in 2024 revenue and ~$500K year-to-date 2025.

About Nextech3D.ai

Nextech3D.ai (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2) is an AI-first technology company focused on event solutions and 3D modeling. Through its Map D platform, Nextech3D.ai powers hundreds of events annually with interactive floor plans, exhibitor management, sponsorships, mobile apps, and ticketing. The Company also delivers AI-powered 3D modeling and spatial computing solutions at scale for major retailers and platforms.

Website: www.Nextech3D.ai
Investor Relations: investors@nextechar.com

For further information, please visit: www.Nextech3D.ai.
Investor Relations: investors@nextechar.com
For more information, visit Nextech3D.ai.
Sign up for Investor News and Info – Click Here

Evan Gappelberg /CEO and Director
866-ARITIZE (274-8493)

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable securities laws, including statements regarding the proposed acquisition of Eventdex, the anticipated timing and consideration, the Company’s blockchain ticketing solution and launch timing, expected benefits and synergies, product integrations, and growth opportunities. Forward-looking statements are based on assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. There can be no assurance that the proposed transaction will be completed as anticipated or at all. Nextech3D.ai disclaims any obligation to update forward-looking statements except as required by law.

Forward-looking Statements The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the completion of the transaction are subject to known and unknown risks, uncertainties and other factors. There can be no assurance that such statements will prove to be accurate, as future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Nextech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws

SOURCE: NexTech3D.AI Corp

View the original press release on ACCESS Newswire

Expanding the Scalability of High-Voltage Marine Propulsion at FLIBS 2025

FORT LAUDERDALE, FLORIDA / ACCESS Newswire / September 30, 2025 / Vision Marine Technologies Inc. (NASDAQ:VMAR) (“Vision Marine” or the “Company”), a technology-driven marine company specializing in high-voltage electric propulsion systems, together with Sterk Boats, a German performance boatbuilder, today announced the world debut of the first dual application of the E-Motion™ 180E electric marine powertrain system. The premium Sterk 31, launching to market as the Sterk 31e,will be revealed in-water at Bahia Mar G Dock during the 2025 Fort Lauderdale International Boat Show (FLIBS) Oct. 29 – Nov. 02, 2025.

This unveiling marks a defining milestone in the evolution of the E-Motion™ platform. Building on Vision Marine’s April 16, 2025 announcement of hull optimization for electric propulsion, the collaboration has advanced to a fully realized, consumer-ready integration. A premium German-engineered performance vessel, the Sterk 31 was custom adapted by a joint effort of both company engineering teams, with Vision Marine completing the outfitting with two E-Motion™ 180E high-voltage electric outboards, powered by a battery system totalling more than 170 kWh.

Sterk 31E powered by Twin E-Motion 180E – Rendering

“This unveiling at FLIBS represents not only a milestone for Vision Marine, but also for the entire boating industry,” said Alexandre Mongeon, Co-Founder and CEO of Vision Marine. “It demonstrates the scalability and versatility of our E-Motion™ technology, showing its ability to power larger and more demanding classes of recreational boats. This achievement lays the groundwork for future integrations across an even wider range of powerboat platforms.”

Milan Sterk, CEO of Sterk Boats, added: “The Sterk 31 was designed from the outset as a high-performance platform, and working with Vision Marine we have proven that premium German design can be seamlessly matched with advanced high-voltage propulsion. This integration demonstrates how electric power can meet the expectations of demanding boaters, and we are proud to debut it at FLIBS.”

The Sterk 31e dual integration expands Vision Marine’s portfolio of 24 completed integrations of the E-Motion™ 180E system across multiple recreational boating platforms, underscoring its unmatched expertise. By anchoring this world debut at FLIBS, Vision Marine highlights its dual role as both a technology enabler for boatbuilders and a direct-to-consumer innovator through Nautical Ventures, the Boating Industry Top Hundred 2024 #1 U.S. dealership network.

About Sterk Boats

STERK Yachts is a premium boat manufacturer known for blending modern design, high-performance engineering, and sustainable innovation. Based in Germany, STERK Yachts is dedicated to redefining the boating experience by integrating cutting-edge technology with meticulous craftsmanship. The company offers a range of high-quality, precision-built boats that cater to both luxury and performance-driven customers.

For more information, please visit www.sterkyachts.com.

About Vision Marine Technologies Inc.

Vision Marine Technologies Inc. (NASDAQ:VMAR) is a disruptive marine company focused on delivering premium experiences across electric and internal combustion engine segments. The Company industrialized the first 180 horsepower high-voltage electric outboard powertrain, the E-Motion™ 180E, integrated in 24 different applications across recreational boating platforms. Vision Marine has also acquired Nautical Ventures, the Boating Industry Top 100’s #1 ranked U.S. dealership network, creating North America’s first vertically integrated marine technology and retail platform.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, integration, performance, and anticipated debut of the Sterk 31 twin-engine electric boat, as well as broader commercialization plans. These statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties. Actual results may differ materially. Vision Marine disclaims any obligation to update these forward-looking statements, except as required by law.

Investor Relations Contact
Bruce Nurse
(303) 919-2913
bn@v-mti.com

https://investors.visionmarinetechnologies.com

SOURCE: Vision Marine Technologies Inc

View the original press release on ACCESS Newswire

Swarm Chorus™ combines machine learning insights and expert systems, empowering facility teams to streamline HVAC service operations directly from their desktops, mitigating the need for multiple application triage.

SAN MARCOS, CA / ACCESS Newswire / September 30, 2025 / Encycle Technologies, Inc., the leader in artificial intelligence and data analytics for commercial HVAC management, announced the release of Swarm Chorus™, a powerful new application that brings machine learning workflow orchestration directly to facilities teams desktops.

Seamlessly integrated with Swarm Sentinel™ into multiple work order management systems, Swarm Chorus transforms how facility teams receive, triage, and dispatch HVAC maintenance across entire building portfolios.

By combining machine learning and expert systems with actionable operational insights, Swarm Chorus delivers fully integrated fault-to-resolution workflows-directly within desktop environments. This revolutionary tool empowers users to confidently prioritize and dispatch HVAC issues, optimizing truck rolls, improving system uptime and budget spend with every service ticket.

Swarm Chorus drives efficient and accurate dispatch decisions for customers within a familiar and convenient interface, unlocking:

• Portfolio-Wide Dispatch Optimization

• Intelligent Triage Prioritization

• Streamlined Maintenance Workflows

• Seamless Desktop Integration

• Closed-Loop Ticket Execution

• Circumvent Comfort Call Noise

“Swarm Chorus delivers for facility teams, what sales technologies have for years delivered to sales managers to keep sales teams fixed on target,” said Ana-Paula Issa, CEO of Encycle. “This technology represents a major leap forward in helping facilities unlock new levels of operational efficiency through automation, insight, and streamlined execution. Gone are the days of chasing hot calls, welcome to the days of organized, racked and stacked workflow, that reduces spending and increases up time.”

Swarm Chorus is the newest innovation added to Encycle’s holistic HVAC management solutions suite, empowering building owners and operators to advance HVAC resiliency by enabling proactive maintenance activities, which improves operational outcomes and prolongs system lifespan.

Swarm Chorus redefines service execution with easy-to-use, scalable tools to improve workflow orchestration. Whether you’re prioritizing a critical failure or scheduling preventative maintenance, Swarm Chorus is built to copilot facility management, ensuring precision in every dispatch decision through better data intelligence.

For more information about Swarm Chorus or to schedule a demo to learn how it improves workflow orchestration, please visit encycle.com or call 1-855-875-4031.

About Encycle:

Deploying autonomous intelligence and analytics, Encycle improves commercial HVAC management, energy efficiency and building comfort to reduce operating costs and carbon footprint. As the only utility-endorsed HVAC optimization software, our patented machine learning solutions seamlessly integrate into maintenance workflows. Encycle enables multi-site commercial and industrial companies to maximize efficiency and reach sustainability goals by improving energy use and budgetary spend decisions. For more information about Encycle, visit encycle.com or follow the company on LinkedIn.

Related Video

https://www.youtube.com/watch?v=klP3FgURhT8

SOURCE: Encycle

View the original press release on ACCESS Newswire